👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

'Pharma bro' Martin Shkreli heads into fraud trial

Published 06/26/2017, 01:55 PM
© Reuters. FILE PHOTO - Martin Shkreli departs with his attorney Brafman after a hearing at U.S. Federal Court in Brooklyn New York
META
-

By Brendan Pierson

NEW YORK (Reuters) - Martin Shkreli, the pharmaceutical entrepreneur vilified as the "pharma bro" for raising the price of a life-saving drug by 5,000 percent, will go on trial on Monday for what U.S. prosecutors called a Ponzi-like scheme at his former hedge fund and a drug company he once ran.

Prosecutors have accused Shkreli of lying to investors in the hedge fund and siphoning millions of dollars in assets from biopharmaceutical company Retrophin Inc to repay them. He has pleaded not guilty.

The trial, which will be heard by U.S. District Judge Kiyo Matsumoto in Brooklyn, is expected to last four to six weeks.

Shkreli, a boyish-looking 34, outraged patients and U.S. lawmakers by raising the price of anti-parisitic drug Daraprim to $750 a pill, from $13.50, in 2015, when he was chief executive of Turing Pharmaceuticals.

The charges that led to his arrest in December 2015 are not related to Turing but focus on Shkreli's management at Retrophin and the hedge fund MSMB Capital Management between 2009 and 2012.

Prosecutors said Shkreli lied about MSMB's finances to lure investors and concealed devastating trading losses from them. They said he paid the investors back with money stolen from Retrophin, which he founded in 2011.

The criminal case has drawn attention in part because of Shkreli's refusal to lay low. He has continued to court the public eye, especially through social media, sometimes complicating his defense.

At a hearing last Monday, prosecutors refused to agree to Shkreli's request to reduce his bail by $3 million, which he said he needs to pay taxes and legal bills, pointing to his own public boasts about his wealth.

Since his arrest, Shkreli has flaunted purchases including a World War II-era Enigma code breaking machine, a Picasso painting and unreleased albums by Wu-Tang Clan and Lil Wayne.

In April, he offered $40,000 to a Princeton University student who solved a mathematical proof. In May, he pledged on Facebook (NASDAQ:FB) to pay $100,000 for tips leading to the arrest of the person who killed former Democratic National Committee employee Seth Rich.

Shkreli was banned from Twitter in January for harassing a female journalist who wrote an op-ed piece for Teen Vogue criticizing President Donald Trump, whom Shkreli has supported.

© Reuters. FILE PHOTO - Martin Shkreli departs with his attorney Brafman after a hearing at U.S. Federal Court in Brooklyn New York

Shkreli's attention-seeking has at times exasperated his lawyer, Benjamin Brafman, who urged Matsumoto last week not to give much weight to his client's "preposterous statements."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.